What a Peptide COA Must Show Under the 2026 HHS Policy: Appendix B Explained
The HHS peptide policy makes a lot-specific COA a condition for compounding. Every test in its Appendix B matrix explained, vs. a typical lab report.
For laboratory research use only. Not for human consumption.
TL;DR: The HHS peptide enforcement discretion policy of 30 October 2026 makes a valid certificate of analysis a legal condition for compounding six peptides. The COA must be lot-specific, come from an FDA-registered original manufacturer whose address is on the document, and report results for a test matrix in Appendix B that covers about twenty attributes – identity by orthogonal methods, assay, net peptide content, peptide-related impurities, nitrosamines, residual solvents, elemental impurities, residual TFA, counter-ion, water, bioburden and endotoxins among them. It is the most detailed public benchmark for a peptide COA to date.
Last verified: 3 November 2026, against the HHS policy document. The matrix applies to bulk substances used by 503A compounders; for research material it is a reference point, not a legal requirement.
Why a Federal Policy Now Defines a Valid COA
Section 503A of the FD&C Act already required bulk drug substances used in compounding to come from a registered establishment with valid certificates of analysis. The 2026 policy turns that general requirement into specifics for six peptides. Condition 3 requires characterisation in a valid COA with results consistent with FDA's guidance-based criteria. Condition 4 requires that the original manufacturer – not a repacker or distributor – be registered with FDA, comply with CGMP and list its physical location on the COA.
The COA also became evidence in the decision itself. In Appendix B, HHS justifies including BPC-157, TB-500 and Epitalon partly with lot-specific certificates from FDA-registered facilities reporting identity, impurity, endotoxin, microbial and residual-solvent results that FDA reviewers had found missing earlier.
The Appendix B Test Matrix
| Quality attribute | Method named in Appendix B | Reference |
|---|---|---|
| Physicochemical properties | Orthogonal analytical methods | ICH Q6A |
| Identification / primary sequence | Orthogonal analytical methods | ICH Q6A |
| Higher-order structure (8+ residues) | Orthogonal analytical methods | USP |
| Aggregates (8+ residues) | Orthogonal analytical methods | USP |
| Assay | HPLC / RP-HPLC against an established quantitative reference standard | USP |
| Biological activity (8+ residues) | Bioassay / orthogonal methods | USP |
| Immunogenicity | In-vitro adaptive and innate assays, ELISA, surface plasmon resonance | FDA immunogenicity guidance |
| Net peptide content | Amino acid analysis, nitrogen analysis, UV spectroscopy or qNMR | USP |
| Peptide-related impurities | Specified, unspecified and total impurities by orthogonal methods | ICH / USP |
| Nitrosamine impurities | Nitrosamine drug-substance-related impurities and small-molecule nitrosamines | FDA acceptable intake limits |
| Residual solvents | Gas chromatography | USP, ICH Q3C |
| Elemental impurities | ICP-MS | USP, ICH Q3D |
| Residual TFA | Ion chromatography | USP |
| Residual fluoride | Ion-selective electrode | USP |
| Counter-ion content | Acetate and other anions or cations | USP |
| Water content | Karl Fischer titration | USP |
| Thiol groups (only if cysteine is present) | Ellman's test or LC-MS | USP |
| Bioburden | Microbial enumeration and specified microorganisms | USP |
| Bacterial endotoxins | Bacterial endotoxins test (e.g. LAL) | USP, FDA guidance |
Purity Is Not Content: Three Numbers That Get Confused
The most common misreading of a peptide COA is to treat HPLC purity as the amount of peptide in the vial. Appendix B separates three numbers that answer different questions:
- HPLC purity: of the UV-absorbing material that elutes, what share is the target peptide rather than related impurities such as deletion or truncated sequences.
- Net peptide content: what share of the weighed powder is actually peptide, after counter-ions such as acetate or TFA and water are accounted for. Appendix B lists amino acid analysis, nitrogen analysis, UV spectroscopy and qNMR as methods.
- Assay: how much of the peptide is present compared with a quantitative reference standard.
A product can show high HPLC purity and still contain noticeably less peptide per vial than the label mass suggests, because salts and water count towards the weight. That is why Appendix B also asks for counter-ion content and water content as separate results.
A Typical Research-Market Lab Report vs. Appendix B
Independent lab reports in the research market usually centre on a compound analysis – identity by mass spectrometry, HPLC purity and a quantity per vial. The panels ChemVerify commissions from Janoshik Analytical for its own samples add endotoxin, heavy-metal (arsenic, cadmium, lead, mercury) and LC-MS contamination screens. Appendix B goes further:
| Attribute | Typical research report | Appendix B |
|---|---|---|
| Identity | Mass spectrometry | Orthogonal methods, including sequence |
| Purity | HPLC area % | Specified, unspecified and total impurities |
| Amount | Quantity per vial | Assay against a reference standard plus net peptide content |
| Endotoxins | If commissioned | Required |
| Metals | Heavy-metal screen if commissioned | Elemental impurities by ICP-MS (ICH Q3D) |
| Residual solvents, TFA, fluoride | Rarely reported | Required |
| Nitrosamines | Rarely reported | Required where applicable |
| Counter-ion and water | Rarely reported | Required |
| Manufacturer identity and site | Usually absent | Required on the COA |
How to Read a Peptide COA Against This Standard
- Is it lot-specific? The batch number on the COA must match the vial.
- Who made the substance, and where? A distributor's letterhead is not the manufacturer.
- Is the salt form stated, and does it match the label (acetate, free base, TFA)?
- Is identity confirmed by more than one method?
- Are purity, assay and net peptide content reported separately – or is a single percentage doing all three jobs?
- Are endotoxins reported with a numeric result and unit, not just "pass"?
- Are residual solvents, TFA and elemental impurities addressed at all?
- Can the report be verified with the issuing laboratory?
Limits of the Standard
Appendix B governs bulk substances that 503A compounders use; research vendors are not bound by it. A COA is also only as good as its authenticity – forged or recycled certificates remain a problem in the research market, which is why verification with the issuing laboratory matters as much as the list of tests. And a full matrix on paper does not replace independent testing of the product actually received.
Frequently Asked Questions
What counts as a valid COA under the HHS peptide policy?
A lot-specific certificate from an FDA-registered original manufacturer, listing the facility's physical location and reporting results consistent with FDA's guidance-based criteria for the attributes in Appendix B, from identity and assay to endotoxins.
Do research peptides have to meet Appendix B?
No. The matrix applies to bulk substances used in 503A compounding. For research material it is a benchmark for judging how complete a lab report is.
What is net peptide content?
The share of the powder's weight that is peptide, after counter-ions and water are subtracted. It differs from HPLC purity, which describes the share of related impurities.
Why test for residual TFA?
Trifluoroacetic acid is used in solid-phase peptide synthesis and purification and can remain as a counter-ion. Appendix B asks for it to be measured by ion chromatography.
Which test detects endotoxins?
The bacterial endotoxins test, typically the Limulus amebocyte lysate (LAL) method, reported against USP requirements.
Check vendors, lab reports and prices on ChemVerify – every independently commissioned test, including failed samples, is published at chemverify.com/tests.
References
Compare Verified Vendors
Browse COA-verified suppliers with exclusive discount codes and transparent pricing.
You Might Also Like
Continue Reading
HHS Peptide Enforcement Discretion Policy (October 2026): Six Peptides, Ten Conditions
HHS will not act against 503A compounding of BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon under ten conditions. What the Oct 2026 policy covers.
Why an Independent COA Matters: Purity Discrepancies, Endotoxin and Impurity Immunogenicity
Reported COA purity gaps, bacterial endotoxin and the immunogenic risk of peptide impurities – the analytical case for independent Certificate of Analysis review.
Beyond Janoshik: The 2026 Third-Party Peptide-Testing Lab Landscape
In 2026, independent peptide labs (Janoshik, Testides, ACS, MZ Biolabs, Colmaric) differ on methods and ISO 17025 accreditation. Compare the landscape here.
The Janoshik Data Breach: What a 2026 Testing-Lab Compromise Means for COA Trust
In February 2026, Janoshik Analytical disclosed a data breach exposing customer order and shipping data. What was reportedly exposed, the ISO 17025 question, and what it means for COA trust.